Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Further clinical development is ongoing
In the STEP clinical trials, semaglutide 2.4 mg (Wegovy) demonstrated average weight loss of approximately 15% of initial body weight over 68 weeks when combined with lifestyle interventions
(PDF) Kessler, R.C., Ressler, K.J., House, S.L., Beaudoin, F.L., An, X., Stevens, J.S., Zeng, D., Neylan, T.C., Linnstaedt, S.D., Germine, L.T., Musey Jr., P.I., Hendry, P.L., Sheikh, S., Storrow, A.B., Jones, C.W., Punches, B.E., Datner, E.M., Mohiuddin, K., Gentile, N.T., McGrath, M.E., van Rooij, S.J., Hudak, L.A., Haran, J.P., Peak, D.A., Domeier, R.M., Pearson, C., Sanchez, L.D., Rathlev, N.K., Peacock, W.F., Bruce, S.E., Miller, M.W., Joormann, J., Barch, D.M., Pizzagalli, D.A., Sheridan, J.F., Smoller, J.W., Pace, T.W.W., Harte, S.E., Elliott, J.M., Harnett, N.G., Lebois, L.A.M., Hwang, I., Sampson, N.A., Koenen, K.C., McLean, S.A
Potential to become a new benchmark in obesity management if approved
10.2 How long will my peptide therapy last
